Preclinical data on GITR-agonist monoclonal antibodies demonstrated in vitro and in vivo antitumor activity which enhances the CD8+ and CD4+ effector T cells and decreases tumour-infiltrating Tregs (72). This evidence concerns the gene CD8A and neoplasm.